1035230-24-0

Basic information

• Product Name: 2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine
• Synonyms: 2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine;2-Isopropoxy-5-Methyl-4-piperidin-4-yl-phenylaMine;5-Methyl-2-(1-Methylethoxy)-4- (4-piperidinyl)- BenzenaMine;EOS-60652
• CAS NO: 1035230-24-0
• Molecular Formula: C₁₅H₂₄N₂O
• Molecular Weight: 248.36386
• Mol File: 1035230-24-0.mol

Chemical Properties

• Boiling Point: 390.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.023±0.06 g/cm3(Predicted)
• PKA: 10.18±0.10(Predicted)
• CAS DataBase Reference: 2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine(1035230-24-0)
• EPA Substance Registry System: 2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine(1035230-24-0)

Safety Data

• Hazardous Substances Data: 1035230-24-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine is used as a chemical intermediate for the synthesis of various drugs and pharmaceutical products, contributing to the development of new therapeutic agents.
Used in Neurological and Psychiatric Disorders Treatment:
In the medical field, 2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine is studied for its potential use in the treatment of neurological and psychiatric disorders, offering a promising avenue for managing such conditions.
Used in Antimicrobial and Antibacterial Applications:
2-isopropoxy-5-Methyl-4-(piperidin-4-yl)benzenaMine is utilized for its antimicrobial and antibacterial properties, making it a valuable compound in the development of new antimicrobial agents to combat resistant infections.

Upstream product

• 1032903-62-0 4-[2-methyl-4-nitro-5-(propan-2-yloxy)phenyl]pyridine 
• 112108-73-3 1-chloro-5-fluoro-2-methyl-4-nitrobenzene 
• 1032903-50-6 1-chloro-2-methyl-4-nitro-5-(propan-2-yloxy)benzene 
• 452-73-3 2-chloro-4-fluorotoluene 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 1032903-52-8 4-(2-methyl-4-nitro-5-isopropoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylic acid tert-butyl ester 
• 119-33-5 4-methyl-2-nitrophenol 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 41661-47-6 piperidin-4-one 
• 301673-14-3 tert-butyl 4-iodopiperidine-1-carboxylate 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 1032903-63-1 4-(4-amino-5-isopropoxy-2-methylphenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1380575-43-8 5-chloro-N²-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine hydrochloride 
• 1445894-96-1 N₂-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N₄-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine 
• 1445895-03-3 5-chloro-N₂-(2-isopropoxy-5-methyl-4-(1-ethylpiperidin-4-yl)phenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1445895-04-4 5-chloro-N₂-(2-isopropoxy-5-methyl-4-(1-isopropylpiperidin-4-yl)phenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1445895-08-8 5-chloro-N₂-(4-(1-(2,2-difluoroethyl)piperidin-4-yl)-2-isopropoxy-5-methylphenyl)-N₄-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine 
• 1190399-47-3 1-(4-(4-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)piperidin-1-yl)-2-(dimethylamino)ethanone 
• 1445895-25-9 2-(4-(5-isopropoxy-4-((4-((2-(isopropylsulfonyl)phenyl)amino)-5-methylpyrimidin-2-yl)amino)-2-methylphenyl)piperidin-1-yl)ethanol 
• 1445895-27-1 N₂-(2-isopropoxy-4-(1-(2-methoxyethyl)piperidin-4-yl)-5-methylphenyl)-N₄-(2-(isopropylsulfonyl)phenyl)-5-methylpyrimidine-2,4-diamine 
• 1032903-64-2 4-(4-{5-chloro-4-[2-(propane-2-sulfonyl)phenylamino]pyrimidin-2-ylamino}-5-isopropoxy-2-methylphenyl)piperidine-1-carboxylic acid tert-butyl ester 
• 1445894-97-2 5-chloro-N₄-(2-(cyclobutylsulfonyl)phenyl)-N₂-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)pyrimidine-2,4-diamine 
• 1380575-43-8 5-chloro-N₂-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N₄-(2-(propane-2-sulfonyl)phenyl)pyrimidine-2,4-diamine dihydrochloride 
• 1032900-25-6 5-chloro-N²-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N⁴-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine 

Relevant articles and documents

Preparation method and application of ceritinib intermediate

The invention relates to a preparation method and application of a ceritinib intermediate, in particular to a preparation process of an intermediate which is 2,5-dichloro-N-(2-(isopropylsulfonyl) phenyl)pyrimidine-4-amine, and belongs to the field of medicine synthesis. The preparation method includes the detailed following steps that a compound 1-a, a compound 1-b, palladium acetate, 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene and alkali are added into a solvent, a reaction is conducted, and then the ceritinib intermediate can be prepared. The route is simple and short, operation is easy,production costs are lowered, and the preparation method is suitable for large-scale industrialized production.

A ceritinib preparing method

The invention relates to a ceritinib preparing method. The method includes (1) reacting 4-bromo-2-isopropoxy-5-methylaniline and acetic anhydride to generate N-(4-bromo-2-isopropoxy-5-cresyl) acetamide, (2) reacting 4-piperidone to generate N-benzyl-4-piperidone, (3) subjecting the N-(4-bromo-2-isopropoxy-5-cresyl) acetamide and the N-benzyl-4-piperidone to a docking reaction, (4) subjecting a product of the former step to dehydroxylation and (5) generating a finally product that is ceritinib from N-(4-(1-phenyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-cresyl) acetamide under the existence of a catalyst. The novel ceritinib preparing method is provided. The synthesis route is low in cost, reaction conditions are mild and easy to control, and the method is suitable for large-scale industrial production.

A preparation method of the midbody color Switzerland for Nepal

The invention relates to a preparation method of ceritinib. The preparation method comprises the following steps: (1) reacting metal powder with N-t-butyloxycarboryl-4 iodine piperidine with a structural formula of SR-1 to generate a metal coupling agent with a structural formula of SR-2; (2) performing a coupling reaction on the metal coupling agent SR-2 and 1-bromo-5-isopropoxy-2-methyl-4-nitrobenzene to generate a compound SR-3; (3) performing hydrogenation reduction on the compound SR-3, and removing BOC amino protection to generate the ceritinib SR-4. According to the invention, a novel preparation method of the ceritinib is developed. The synthetic route is very short; the yield is high; raw materials can be easily obtained and are low in cost; reaction conditions are very mild and easy to control; therefore, the preparation method is suitable for large-scale industrial production.

ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF

An ALK kinase inhibitor compound as represented by Formula I, pharmaceutical composition containing the compound, and preparation method and use thereof in the preparation of drugs serving as an ALK inhibitor for treating cancer.

Ceritinib intermediate and preparation method and application thereof

The present invention discloses a ceritinib intermediate and a preparation method and application thereof. The ceritinib intermediate has a structure shown as a formula I, R and R2 are as defined in the specification and claims. The ceritinib intermediate is prepared from a compound of a formula 1 and a benzyl halide compound by substitution reaction and then reduction. After further reduction of the nitro by catalytic hydrogenation and removal of amino-protection, the compound of the formula I is reacted with a compound of a formula III to obtain ceritinib. According to the method, raw materials are readily available and inexpensive, the method does not require special equipment, production cost is greatly reduced, and the method is suitable for industrial application.

PROCESS FOR PREPARATION OF CERITINIB

The present application relates to a process for preparation of ceritinib and intermediates thereof. Specifically, the present application relates to a process for preparation of N-(4-(1-benzyl- 1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)acetamide (VC) comprising treating N-(4-(bromomethyl)-2-isopropoxy-5-methylphenyl)acetamide (IIID) with 1- benzylpiperidin-4-one (IVA). The present application also relates to a process for conversion of N-(4-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-acetamide (VC) to ceritinib or an acid-addition salt thereof.

Ceritinib synthesis intermediate and preparation method thereof

The invention provides a synthesis intermediate 8 of an anti-tumor drug ceritinib, a preparation method thereof, and an application of the intermediate 8 in synthesizing ceritinib. The preparation method of the intermediate 8 comprises the following steps: step (1), a compound 1 and an acid HX are subjected to salt formation, such that a compound 7 is obtained; step (2), the compound 7 is reduced through sodium borohydride, such that the compound 8 is obtained. The reaction formula is as the following. With prior arts, expensive platinum oxide is needed as a hydrogenation catalyst for preparing an intermediate 2 in a next step. With the intermediate 8, the above problem is avoided. Therefore, the intermediate 8 is suitable to be used in industrialized production of ceritinib.

DEUTERATED DIAMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS

The present invention related to deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds. In particular, disclosed are the deuterated diaminopyrimidine compounds shown as formula (I), and the pharmaceutical compositions comprising such compounds or crystal form, pharmaceutically acceptable salts, hydrates or solvates thereof. The compounds of the present invention can be used for treating and/or preventing protein kinase-associated diseases, such as cell proliferative disease, cancer, immune disease and the like.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl) phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials

The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described. In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684). Compound 15b is currently in phase 1 and phase 2 clinical trials with substantial antitumor activity being observed in ALK-positive cancer patients.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.